NADMED raises €3.5M to expand its technology to new markets
Health Incubator Helsinki alumni, NADMED, has successfully finalized a Series A funding round of €3.5 million, led by Finnish science-based startup investor, Nordic Science Investments (NSI).
NADs are essential molecules in each cell of the body, and together with glutathiones, they play an essential role in energy production, cellular repair, and growth. Imbalances in NAD and glutathione levels have been linked to various diseases, including metabolic disorders, cancer, heart and brain diseases, and muscle atrophy.
Despite the recognized need for a NAD measurement method among physicians and the pharmaceutical industry, a quick and reliable solution has been lacking in the market. Originating from Professor Anu Suomalainen Wartiovaara’s lab at the University of Helsinki, NADMED has addressed this gap by developing the world’s first method to accurately measure the full range of NADs from fresh blood samples within hours. The company’s technology is available as CE-marked kits and through laboratory service.
New funding accelerates the journey to international markets
NADMED, founded in 2022, currently serves customers in 27 countries, including clinical laboratories, universities, research institutions, and pharmaceutical companies. Now the company has closed a Series A round of 3.5 million euros to introduce its technology in the US and other international markets.
The latest funding round was led by Finnish science-based startup investor Nordic Science Investments (NSI). Additional funding was secured from previous investors Voima Ventures and University of Helsinki Funds, from a number of private European investors, and a grant from Business Finland.
“We are pleased and grateful for the funding from these insightful investors to spread and further develop the unique technology to measure all REDOX metabolites – something that was not possible before. This investment will enable us to bring new capabilities to diagnostics, therapy monitoring, personalized medicine, and advancement of metabolic science for the benefit of mankind”, says Jari Närhi, CEO of NADMED.
Photo: NADMED Oy
